Tardive Dyskinesia Therapeutics Market 2026 unlocking new treatment pathways

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Tardive Dyskinesia Therapeutics Market During The Forecast Period 2026–2030?

The tardive dyskinesia therapeutics market size has experienced substantial growth in recent years. Its value is projected to increase from $3.12 billion in 2025 to $3.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. The expansion observed historically can be attributed to several factors, including the scarcity of treatment options for tardive dyskinesia, a dependence on conventional antipsychotic management, inadequate patient awareness, the rising prevalence of antipsychotic use, and limited specialized treatment centers.

The tardive dyskinesia therapeutics market is projected to experience substantial expansion over the upcoming years, reaching a size of $4.39 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This projected expansion is primarily due to several factors, including the creation of innovative treatments for tardive dyskinesia, increased investment in research and development for neurological conditions, a growing inclination towards homecare environments, the proliferation of specialized treatment facilities, improved patient oversight, and advancements in digital therapeutics. Key developments anticipated during this period encompass the increasing use of deutetrabenazine and valbenazine, a heightened emphasis on individualized neurological treatments, the broadening availability of homecare and remote treatment alternatives, a rising understanding of tardive dyskinesia caused by medication, and a strong focus on ensuring safety and adherence in long-term therapy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp

What Drivers Are Expected To Influence The Tardive Dyskinesia Therapeutics Market During The Forecast Period?

The rising occurrence of mental health conditions is anticipated to drive the expansion of the tardive dyskinesia therapeutics market in the future. These disorders are defined as states impacting an individual’s cognition, feelings, conduct, or daily functionality, frequently leading to considerable discomfort or challenges in everyday living. The surge in mental health issues stems from growing social isolation, as the move towards digital interactions and rapid lifestyles has diminished valuable face-to-face contacts, fostering heightened sensations of solitude and emotional pressure. Tardive dyskinesia therapeutics aid individuals with mental disorders by controlling involuntary movement symptoms resulting from prolonged antipsychotic medication, consequently enhancing compliance with treatment and improving their overall quality of life. For example, in 2024, data from the National Alliance On Mental Illness, a US-based organization, indicates that psychosis spectrum and mood disorders are responsible for almost 600,000 annual hospitalizations among those aged 18-44 in the U.S. Consequently, the expanding occurrence of mental health conditions fuels the tardive dyskinesia therapeutics market.

What Market Segments Are Evaluated Within The Tardive Dyskinesia Therapeutics Market?

The tardive dyskinesia therapeutics market covered in this report is segmented –

1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs

2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form

3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia

4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings

Subsegments:

1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel

2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel

3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration

What Industry Trends Are Redefining The Tardive Dyskinesia Therapeutics Market?

Leading companies in the tardive dyskinesia therapeutics market are prioritizing the development of advanced products, including once-daily treatment choices, to help maintain more consistent drug levels within the body. Once-daily treatment options refer to medications or therapies designed for administration just once daily, thereby simplifying dosing schedules and improving patient adherence. For instance, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of AUSTEDO XR tablets for treating adults suffering from tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. The recent authorization of AUSTEDO XR provides patients with proven effectiveness in managing involuntary movements, alongside the added convenience of a once-daily, single-pill dosage. This new formulation delivers clinically therapeutic doses, which have been confirmed through pivotal clinical trials. Additionally, it is now accessible in four distinct tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

Who Are The Top Market Participants Influencing The Tardive Dyskinesia Therapeutics Market?

Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.

Read the full tardive dyskinesia therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-therapeutics-global-market-report

Which Region Is Forecast To Lead The Tardive Dyskinesia Therapeutics Market In Terms Of Market Size?

North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tardive Dyskinesia Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24718&type=smp

Browse Through More Reports Similar to the Global Tardive Dyskinesia Therapeutics Market 2026, By The Business Research Company

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Bipolar Disorder Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795